Topical Dutasteride for Hair Regrowth - Quick Reference Sheet
evipedia.ai
← Back

Topical Dutasteride for Hair Regrowth

Created on 09/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Applying dutasteride to the scalp aims to block the hair-shrinking hormone at the hair follicle while sparing the rest of the body. Three small, short controlled studies found more regrowth than placebo, though pooled comparisons still rank the injected route below oral dutasteride. Harms come mostly from the injections themselves. Sparsely studied, with an identifiable commercial tilt. (Full Review)

Protocol

Standard intradermal protocol
0.01%, 0.5–1 mL per session
0.05 mL aliquots across a 1 cm² grid over affected scalp; one session every 3 months after an initial closer-spaced induction
Topical solution protocol
0.01–0.05% w/v once daily
Alcoholic solution for 24 weeks — the only formulation with controlled efficacy data
Microneedling-assisted protocol
0.01% after 1.5 mm microneedling
Applied immediately after needling, repeated at intervals of several weeks
Time to effect
Measurable density gain
12 months
Density gain against the fixed-point baseline; a judgement on the protocol matches this timescale
Density stable
6 months
Shedding has stopped and density is stable; photographic assessment and trichoscopy repeated
Shedding slows
2–3 months
Typically the first change; visible density change requires two to three full hair cycles

Benefits

Contraindications
  • Women who are pregnant, planning pregnancy, or breastfeeding, and any woman of childbearing potential not using reliable contraception
  • Men whose partner is pregnant
  • Known hypersensitivity to dutasteride, finasteride or other 4-azasteroid 5-alpha reductase inhibitors
  • Severe hepatic impairment (Child-Pugh Class C)
  • Men under active surveillance for prostate cancer or within 12 months of a prostate biopsy
  • Children and adolescents under 18 years
  • Active scalp infection, open erosions or uncontrolled inflammatory scalp disease, until healed
    •
Key Interactions
  • Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin, nefazodone)
  • Moderate CYP3A4 inhibitors (verapamil, diltiazem, grapefruit juice)
  • Alpha-blockers (tamsulosin, alfuzosin, doxazosin)
  • Topical ketoconazole 2% shampoo (over-the-counter)
  • Topical minoxidil (over-the-counter)
  • Over-the-counter analgesics (ibuprofen, naproxen, aspirin) and alcohol-containing scalp products
  • Supplements with additive 5-alpha reductase inhibition (saw palmetto, beta-sitosterol, pygeum, green tea catechins, reishi)
  • Biotin (vitamin B7) at hair-supplement doses
  • Other interventions (microneedling, platelet-rich plasma, hair transplantation)
    •

Risk & Side Effects

  • High:
  • Medium: Injection-site pain and local reactions
    •
  • Low: Paradoxical patchy hair loss and dermal atrophy at treated sites; sexual adverse effects from absorbed drug; local scalp irritation from alcohol-based vehicles
    •
  • Speculative: Teratogenic exposure of a pregnant partner; persistent symptoms after discontinuation; depressed mood and suicidal ideation; gynecomastia and breast tenderness; suppressed prostate-specific antigen masking prostate screening; increased incidence of high-grade prostate cancer; reduced sperm count and semen volume
    •

Monitoring

Marker Target Why
Serum dihydrotestosterone Retain at least 60% of the individual's own pre-treatment value Shows how much of the scalp dose behaved systemically
Total testosterone 600–900 ng/dL (men) Detects compensatory rise or unexpected suppression
Prostate-specific antigen Below 1.0 ng/mL under age 60; below 1.5 ng/mL thereafter Establishes a reference value that later readings can be judged against
Alanine aminotransferase 10–26 U/L Confirms the metabolic route clearing absorbed drug is intact
Ferritin 70–150 ng/mL Iron deficiency causes shedding that masquerades as treatment failure
Thyroid-stimulating hormone 0.5–2.0 mIU/L Thyroid dysfunction produces diffuse hair loss independent of androgens
Trichoscopic hair density No established target; track change from the individual's own fixed-point baseline The only direct measure of whether the intervention is working

Cadence: Baseline before the first dose; sexual function score and prostate-specific antigen, where relevant, repeated at 3 months, then at 6 months alongside repeat photographs and trichoscopy; after the first year, blood markers every 6–12 months and photographs annually

Qualitative Assessment

  • Hair on the pillow and in the shower drain, counted weekly for the first 3 months rather than estimated
  • Whether scalp skin is visible under overhead lighting, photographed monthly under identical conditions
  • Styling behaviour — whether hair holds a parting, needs less concealment, or feels thicker to the hand
  • Scalp comfort at treated sites: stinging, itching, tenderness or new dimpled areas
  • Libido, erectile quality and mood, recorded as a simple weekly score so that drift is visible rather than remembered
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.